Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells

Blood

Volumn 101, Issue 10, 2003, Pages 4105-4114

  Liu, Qun ^b   Gazitt, Yair ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; CASPASE 3; CASPASE 9; CYTOCHROME C; DEXAMETHASONE; PACLITAXEL; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CYTOSOL; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; WESTERN BLOTTING; CELL CULTURE; DRUG EFFECT; DRUG RESISTANCE; GENETIC TRANSFECTION; GENETICS; KINETICS; PATHOLOGY; PHYSIOLOGY; PROTO ONCOGENE;

APOPTOSIS; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENES, BCL-2; HUMANS; KINETICS; MULTIPLE MYELOMA; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PACLITAXEL; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038603202     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3067     Document Type: Article

References (46)

1. Gregory W, Richards M, Malpas J. Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992;10:336-342.
2. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment for multiple myeloma. Blood. 1992;80:887-892.
3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective randomized trial of autologous transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
4. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992;80:879-886.
5. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322-1325.
6. Reed JC. Bcl-2 family proteins. Oncogene. 1998;17:3225-3236.
7. Reed JC, Kitada S, Miyashita T. Regulation of chemoresistance by the Bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol. 1994;5:s61-s65.
8. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy induced apoptosis in human leukemia cell line. Blood. 1993;81:151-157.
9. Tian E, Hu W-X, Gazitt Y. Bcl-2 plays a critical role in growth and in spontaneous or induced apoptosis in myeloma cell lines: a study with inducible Bcl-2 transfection constructs. Int J Oncol. 1996;9:165-169.
10. Tian E, Gazitt Y. The role of P53, Bcl-2 and bax in dexamethasone induced apoptosis in myeloma cell lines. Int J Oncol. 1996;8:719-726.
11. Hu W-X, Gazitt Y. Bcl-2 plays a major role in resistance to dexamethasone induced apoptosis in multiple myeloma cell lines. Int J Oncol. 1996;9:375-381.
12. Gazitt Y, Rothenberg ML, Hilsenbeck S, et al. Bcl-2 overexpression is associated with resistance to paclitaxel but not gemcitabine in multiple myeloma cell lines. Int J Oncol. 1998;13:839-848.
13. Liu Q, Gazitt Y. Adenovirus-mediated delivery of p53 results in a substantial apoptosis to myeloma cells and is not cytotoxic to flow-sorted CD34+ hematopoietic progenitor cells and normal lymphocytes. Exp Hematol. 2000;28:1354-1362.
14. Liu Q, El-Deiry W, Gazitt Y. Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines. Exp Hematol. 2001;29:962-970.
15. Gazitt Y, Fey V, Thomas C, Alvarez R. Bcl-2 overexpression is associated with resistance to dexamethasone but not melphalan in multiple myeloma cell lines. Int J Oncol. 1998;13:397-405.
16. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia. 1999;13:1817-1824.
17. Gazitt Y, Shaughnessy P, Montgomery W. Apoptosis induced by TRAIL and TNFα in human multiple myeloma cells is not blocked by Bcl-2. Cytokine. 1999;11:1010-1019.
18. Koty PP, Zhang H, Levitt ML. Antisense Bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines. Lung Cancer. 199;23:115-127.
19. Julien T, Frankel B, Longo S, et al. Antisense-mediated inhibition of the Bcl-2 gene induces apoptosis in human malignant glioma. Surg Neurol. 2000;53:360-368.
20. Duggan BJ, Maxwell P, Kelly JD, et al. The effect of antisense Bcl-2 oligodeoxynucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma. J Urol. 2001;166:1098-1105.
21. Pepper C, Thomas A, Hoy T, et al. Antisense mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukemia. Br J Haematol. 1999;107:611-615.
22. Uchida T, Gao JP, Wang C, et al. Antitumor effect of Bcl-2 antisense phosphorothioate oligodeoxynucleotides on human renal-cell carcinoma cells in vitro and in mice. Mol Urol. 2001;5:71-78.
23. Gleave ME, Miyake H, Goldie J, et al. Targeting Bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense Bcl-2 oligodeoxynucleotides. Urology. 1999;54(suppl 6A):36-46.
24. Miyake H, Monia BP, Gleave ME. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligodeoxynucleotides plus taxol after castration in the Shionogi tumor model. Int J Cancer. 2000;86:855-862.
25. Leung S, Miyake H, Zellweger T, et al. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotides and paclitaxel in the LN-CaP prostate tumor model. Int J Cancer. 2001;91:846-850.
26. Bilim V, Kasahara T, Noboru H, et al. Caspase involved synergistic cytotoxicity of Bcl-2 antisense oligodeoxynucleotides and adriamycin on transitional cell cancer cells. Cancer Lett. 2000;155:191-198.
27. Jansen B, Schlagbauer-Wadl H, Brown BD, et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med. 1998;4:232-234.
28. Webb A, Cunningham D, Cotter F, et al. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 1997;349:1137-1141.
29. Cotter FE, Waters J, Cunningham D. Human Bcl-2 antisense therapy for lymphomas. Biochim Biophys Acta. 1999;1489:97-106.
30. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2000;18:1812-1823.
31. Jansen B, Wacheck V, Heere-Ress E, et al. Chemosensitisation of malignant melanoma by Bcl-2 antisense therapy. Lancet. 2000;356:1728-1733.
32. Miyake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst. 2000;92:34-41.
33. Gazitt Y, Vesole D, Liu Q. Bcl-2 antisense oligodeoxynucleotides (ASO) enhances apoptosis and cytotoxicity in drug-resistant myeloma cells [abstract]. Blood. 2001;98:641a.
34. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF-1 a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
35. Thornberry NA. The caspase family of cysteine proteases. Br Med Bull. 1997;53:478-490.
36. Thornberry NA, Lazebnik U. Caspases: enemies within. Science. 1998;281:1312-1316.
37. Tu Y, Xu FH, Liu J, et al. Upregulated expression of Bcl-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood. 1996;88:1805-1812.
38. Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 2000;102:849-862.
39. Raynaud FI, Orr RM, Goddard PM, et al. Pharmacokinetics of G3139, a phosphorothloate oligodeoxynucleotide antisense to Bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther. 1997;281:420-427.
40. Akgul C, Moulding DA, White MR, Edwards SW. In vivo localisation and stability of human Mcl-1 using green fluorescent protein (GFP) fusion proteins. FEBS Lett. 2000;478:72-76.
41. Zhou P, Qian L, Kozopas KM, Craig RW. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood. 1997;89:630-643.
42. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlation with in vitro and in vivo chemoresponses. Blood. 1998;91:3379-3389.
43. Kaufmann SH, Karp JE, Svingen PA, et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood. 1998;91:991-1000.
44. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood. 99;2002:1885-1893.
45. L is an essential survival protein of human myeloma cells. Blood. 2002;100:194-199.
46. Puthier D, Derenne S, Barille S, et al. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol. 1999;107:392-395.